News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Pharmaceutical Industries Limited (TEVA) Announces Launch of Generic Actos® in the United States


8/17/2012 9:35:43 AM

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of an authorized generic of Actos® (pioglitazone-hydrochloride tablets) 15, 30 and 45mg. Actos® is marketed by Takeda Pharmaceuticals U.S.A., Inc. and used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. The brand product had annual sales of approximately $2.7 billion in the United States, based on IMS sales data as of June 30, 2012.

Read at BioSpace.com


comments powered by Disqus
 
 
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES